Regeneron Pharmaceuticals Inc (REGN)

338.22 -10.08  -2.89% NASDAQ Nov 14, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/06/2020 08:30 EST Misc Regeneron Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2019
02/06/2020 Earnings Regeneron Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
11/05/2019 08:30 EST Misc Regeneron Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Regeneron Pharmaceuticals Inc Third Quarter Earnings in 2019 Release
08/06/2019 08:30 EDT Misc Regeneron Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
08/06/2019 Earnings Regeneron Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
06/14/2019 10:30 EDT Misc Regeneron Pharmaceuticals Inc Annual General Meeting in 2018
05/07/2019 08:30 EDT Misc Regeneron Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
05/07/2019 Earnings Regeneron Pharmaceuticals Inc First Quarter Earnings in 2019 Release
02/07/2019 Misc Regeneron Pharmaceuticals Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.regeneron.com
  • Investor Relations URL: http://newsroom.regeneron.com/
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Large Cap/Blend
  • Next Earnings Release: Feb. 06, 2020
  • Last Earnings Release: Nov. 05, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Top Fund Holders

Symbol Name Weighting
PFPWX Parnassus Endeavor Institutional 4.61%
IBB iShares Nasdaq Biotechnology ETF 4.49%
OARLX Oakmark Select Service 3.86%
FBT First Trust NYSE Arca Biotech ETF 3.60%
HQH Tekla Healthcare Investors 2.86%
LGRCX Loomis Sayles Growth C 2.44%
OARMX Oakmark Service 2.28%
APGBX AB Large Cap Growth B 2.06%
XBI SPDR® S&P Biotech ETF 1.98%
FXH First Trust Health Care AlphaDEX® ETF 1.96%
THISX T. Rowe Price Health Sciences I 1.36%
RSP Invesco S&P 500® Equal Weight ETF 0.24%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.